Cell Therapy Manufacturing Market - Industry Size, Share, Trend and Forecast 2026 | TechSci Research

1
2016 2026
Global Cell Therapy Manufacturing Market
FORECAST AND OPPORTUNITIES
www.techsciresearch.com
MARKET INTELLIGENCE . CONSULTING
2

• Table of Contents

S. No. Contents Contents Contents
1. Product Overview Product Overview Product Overview
2. Research Methodology Research Methodology Research Methodology
3. Executive Summary Executive Summary Executive Summary
4. Impact of COVID-19 on Global Cell Therapy Manufacturing Market Impact of COVID-19 on Global Cell Therapy Manufacturing Market Impact of COVID-19 on Global Cell Therapy Manufacturing Market
5. Voice of Customer Voice of Customer Voice of Customer
5.1. Brand Awareness Brand Awareness
5.2. Commonly Used Cell Therapies Commonly Used Cell Therapies
5.3. Preferences Based on Source of Cell Among Medical Professionals Preferences Based on Source of Cell Among Medical Professionals
6. Global Cell Therapy Manufacturing Market Outlook Global Cell Therapy Manufacturing Market Outlook Global Cell Therapy Manufacturing Market Outlook
6.1. Market Size Forecast Market Size Forecast
6.1.1. By Value
6.2. Market Share Forecast Market Share Forecast
6.2.1. By Therapy (T-Cell Therapies, Dendritic Cell Therapies, Tumor Cell Therapies, Stem Cell Therapies)
6.2.2. By Source of Cell (Autologous v/s Allogenic)
6.2.3. By Scale of Operation (Preclinical, Clinical, Commercial)
6.2.4. By Source (In-House v/s Contract Manufacturing)
6.2.5. By Application (Oncology, Cardiovascular Diseases, Orthopedic Diseases, Others)
6.2.6. By End User (Pharmaceutical Biotechnology Companies, Academic Research Institutes, Others)
6.2.7. By Region
6.2.8. By Company (2020)
6.3. Product Market Map Product Market Map Product Market Map
2
3

• Table of Contents

S. No. Contents Contents Contents Contents
6.3.1. By Therapy By Therapy By Therapy By Therapy
6.3.2. By Scale of Operation By Scale of Operation By Scale of Operation By Scale of Operation
6.3.3. By Source By Source By Source By Source
6.3.4. By Application By Application By Application By Application
6.3.5. By Region By Region By Region By Region
7. North America Cell Therapy Manufacturing Market Outlook North America Cell Therapy Manufacturing Market Outlook North America Cell Therapy Manufacturing Market Outlook North America Cell Therapy Manufacturing Market Outlook North America Cell Therapy Manufacturing Market Outlook North America Cell Therapy Manufacturing Market Outlook
7.1. Market Size Forecast Market Size Forecast Market Size Forecast
7.1.1. By Value By Value By Value By Value
7.2. Market Share Forecast Market Share Forecast Market Share Forecast Market Share Forecast Market Share Forecast
7.2.1. By Therapy By Therapy By Therapy By Therapy
7.2.2. By Source of Cell By Source of Cell By Source of Cell By Source of Cell
7.2.3. By Scale of Operation By Scale of Operation By Scale of Operation By Scale of Operation
7.2.4. By Source By Source By Source By Source
7.2.5. By Application By Application By Application By Application
7.2.6. By End User By End User By End User By End User
7.2.7. By Country By Country By Country By Country
7.3. North America Country Analysis North America Country Analysis North America Country Analysis North America Country Analysis North America Country Analysis
7.3.1. United States Cell Therapy Manufacturing Market Outlook United States Cell Therapy Manufacturing Market Outlook United States Cell Therapy Manufacturing Market Outlook United States Cell Therapy Manufacturing Market Outlook
7.3.1.1. Market Size Forecast Market Size Forecast Market Size Forecast
7.3.1.1.1. 7.3.1.1.1. By Value
3
4

• Table of Contents

S. No. Contents Contents Contents
7.3.1.2. Market Share Forecast Market Share Forecast
7.3.1.2.1. By Therapy
7.3.1.2.2. By Source of Cell
7.3.1.2.3. By Scale of Operation
7.3.1.2.4. By Source
7.3.1.2.5. By Application
7.3.1.2.6. By End User
7.3.2. Canada Cell Therapy Manufacturing Market Outlook Canada Cell Therapy Manufacturing Market Outlook Canada Cell Therapy Manufacturing Market Outlook
7.3.2.1. Market Size Forecast Market Size Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share Forecast Market Share Forecast
7.3.2.2.1. By Therapy
7.3.2.2.2. By Source of Cell
7.3.2.2.3. By Scale of Operation
7.3.2.2.4 By Source
9.3.2.2.5. By Application
7.3.2.2.6. By End User
7.3.3. Mexico Cell Therapy Manufacturing Market Outlook Mexico Cell Therapy Manufacturing Market Outlook Mexico Cell Therapy Manufacturing Market Outlook
7.3.3.1. Market Size Forecast Market Size Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share Forecast Market Share Forecast
7.3.3.2.1. By Therapy
4
5

• Table of Contents

S. No. Contents Contents Contents
7.3.3.2.2. By Source of Cell
7.3.3.2.3. By Scale of Operation
7.3.3.2.4. By Source
7.3.3.2.5. By Application
7.3.3.2.6. By End User
8. Europe Cell Therapy Manufacturing Market Outlook Europe Cell Therapy Manufacturing Market Outlook Europe Cell Therapy Manufacturing Market Outlook Europe Cell Therapy Manufacturing Market Outlook Europe Cell Therapy Manufacturing Market Outlook
8.1. Market Size Forecast Market Size Forecast Market Size Forecast
8.1.1. By Value By Value By Value
8.2. Market Share Forecast Market Share Forecast Market Share Forecast Market Share Forecast
8.2.1. By Therapy By Therapy By Therapy
8.2.2. By Source of Cell By Source of Cell By Source of Cell
8.2.3. By Scale of Operation By Scale of Operation By Scale of Operation
8.2.4. By Source By Source By Source
8.2.5. By Application By Application By Application
8.2.6. By End User By End User By End User
8.2.7. By Country By Country By Country
8.3. Europe Country Analysis Europe Country Analysis Europe Country Analysis Europe Country Analysis
8.3.1. Germany Cell Therapy Manufacturing Market Outlook Germany Cell Therapy Manufacturing Market Outlook Germany Cell Therapy Manufacturing Market Outlook
8.3.1.1. Market Size Forecast Market Size Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share Forecast Market Share Forecast
8.3.1.2.1. By Therapy
8.3.1.2.2. By Source of Cell
5
6

• Table of Contents

S. No. Contents Contents Contents
8.3.1.2.3. By Scale of Operation
8.3.1.2.4. By Source
8.3.1.2.5. By Application
8.3.1.2.6. By End User
8.3.2. France Cell Therapy Manufacturing Market Outlook France Cell Therapy Manufacturing Market Outlook France Cell Therapy Manufacturing Market Outlook
8.3.2.1. Market Size Forecast Market Size Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share Forecast Market Share Forecast
8.3.2.2.1. By Therapy
8.3.2.2.2. By Source of Cell
8.3.2.2.3. By Scale of Operation
8.3.2.2.4 By Source
8.3.2.2.5. By Application
8.3.2.2.6. By End User
8.3.3. United Kingdom Cell Therapy Manufacturing Market Outlook United Kingdom Cell Therapy Manufacturing Market Outlook United Kingdom Cell Therapy Manufacturing Market Outlook
8.3.3.1. Market Size Forecast Market Size Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share Forecast Market Share Forecast
8.3.3.2.1. By Therapy
8.3.3.2.2. By Source of Cell
8.3.3.2.3. By Scale of Operation
8.3.3.2.4. By Source
8.3.3.2.5. By Application
8.3.3.2.6. By End User
6
7

• Table of Contents

S. No. Contents Contents Contents
8.3.4. Spain Cell Therapy Manufacturing Market Outlook Spain Cell Therapy Manufacturing Market Outlook Spain Cell Therapy Manufacturing Market Outlook
8.3.4.1. Market Size Forecast Market Size Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share Forecast Market Share Forecast
8.3.4.2.1. By Therapy
8.3.4.2.2. By Source of Cell
8.3.4.2.3. By Scale of Operation
8.3.4.2.4 By Source
8.3.4.2.5. By Application
8.3.4.2.6. By End User
8.3.5. Italy Cell Therapy Manufacturing Market Outlook Italy Cell Therapy Manufacturing Market Outlook Italy Cell Therapy Manufacturing Market Outlook
8.3.5.1. Market Size Forecast Market Size Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share Forecast Market Share Forecast
8.3.5.2.1. By Therapy
8.3.5.2.2. By Source of Cell
8.3.5.2.3. By Scale of Operation
8.3.5.2.4. By Source
8.3.5.2.5. By Application
8.3.5.2.6. By End User
9. Asia Pacific Cell Therapy Manufacturing Market Outlook Asia Pacific Cell Therapy Manufacturing Market Outlook Asia Pacific Cell Therapy Manufacturing Market Outlook Asia Pacific Cell Therapy Manufacturing Market Outlook Asia Pacific Cell Therapy Manufacturing Market Outlook
9.1. Market Size Forecast Market Size Forecast Market Size Forecast
9.1.1. By Value By Value By Value
9.2. Market Share Forecast Market Share Forecast Market Share Forecast Market Share Forecast
7
8

• Table of Contents

S. No. Contents Contents Contents
9.2.1. By Therapy By Therapy By Therapy
9.2.2. By Source of Cell By Source of Cell By Source of Cell
9.2.3. By Scale of Operation By Scale of Operation By Scale of Operation
9.2.4. By Source By Source By Source
9.2.5. By Application By Application By Application
9.2.6. By End User By End User By End User
9.2.7. By Country By Country By Country
9.3. Asia Pacific Country Analysis Asia Pacific Country Analysis Asia Pacific Country Analysis Asia Pacific Country Analysis
9.3.1. China Cell Therapy Manufacturing Market Outlook China Cell Therapy Manufacturing Market Outlook China Cell Therapy Manufacturing Market Outlook
9.3.1.1. Market Size Forecast Market Size Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share Forecast Market Share Forecast
9.3.1.2.1. By Therapy
9.3.1.2.2. By Source of Cell
9.3.1.2.3. By Scale of Operation
9.3.1.2.4. By Source
9.3.1.2.5. By Application
9.3.1.2.6. By End User
9.3.2. Japan Cell Therapy Manufacturing Market Outlook Japan Cell Therapy Manufacturing Market Outlook Japan Cell Therapy Manufacturing Market Outlook
9.3.2.1. Market Size Forecast Market Size Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share Forecast Market Share Forecast
9.3.2.2.1. By Therapy
9.3.2.2.2. By Source of Cell
8
9

• Table of Contents

S. No. Contents Contents Contents
9.3.2.2.3. By Scale of Operation
9.3.2.2.4 By Source
9.3.2.2.5. By Application
9.3.2.2.6. By End User
9.3.3. South Korea Cell Therapy Manufacturing Market Outlook South Korea Cell Therapy Manufacturing Market Outlook South Korea Cell Therapy Manufacturing Market Outlook
9.3.3.1. Market Size Forecast Market Size Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share Forecast Market Share Forecast
9.3.3.2.1. By Therapy
9.3.3.2.2. By Source of Cell
9.3.3.2.3. By Scale of Operation
9.3.3.2.4. By Source
9.3.3.2.5. By Application
9.3.3.2.6. By End User
9.3.4. Australia Cell Therapy Manufacturing Market Outlook Australia Cell Therapy Manufacturing Market Outlook Australia Cell Therapy Manufacturing Market Outlook
9.3.4.1. Market Size Forecast Market Size Forecast
9.3.4.1.1. By Value
9.3.4.2. Market Share Forecast Market Share Forecast
9.3.4.2.1. By Therapy
9.3.4.2.2. By Source of Cell
9.3.4.2.3. By Scale of Operation
9.3.4.2.4 By Source
9.3.4.2.5. By Application
9.3.4.2.6. By End User
9
10

• Table of Contents

S. No. Contents Contents Contents Contents Contents
9.3.5. India Cell Therapy Manufacturing Market Outlook India Cell Therapy Manufacturing Market Outlook India Cell Therapy Manufacturing Market Outlook India Cell Therapy Manufacturing Market Outlook India Cell Therapy Manufacturing Market Outlook
9.3.5.1. 9.3.5.1. Market Size Forecast Market Size Forecast Market Size Forecast
9.3.5.1.1. 9.3.5.1.1. By Value
9.3.5.2. 9.3.5.2. Market Share Forecast Market Share Forecast Market Share Forecast
9.3.5.2.1. 9.3.5.2.1. By Therapy
9.3.5.2.2. 9.3.5.2.2. By Source of Cell
9.3.5.2.3. 9.3.5.2.3. By Scale of Operation
9.3.5.2.4. 9.3.5.2.4. By Source
9.3.5.2.5. 9.3.5.2.5. By Application
9.3.5.2.6. 9.3.5.2.6. By End User
10. South America Cell Therapy Manufacturing Market Outlook South America Cell Therapy Manufacturing Market Outlook South America Cell Therapy Manufacturing Market Outlook South America Cell Therapy Manufacturing Market Outlook South America Cell Therapy Manufacturing Market Outlook South America Cell Therapy Manufacturing Market Outlook South America Cell Therapy Manufacturing Market Outlook
10.1. Market Size Forecast Market Size Forecast Market Size Forecast Market Size Forecast Market Size Forecast
10.1.1. 10.1.1. By Value By Value By Value By Value
10.2. Market Share Forecast Market Share Forecast Market Share Forecast Market Share Forecast Market Share Forecast Market Share Forecast
10.2.1. 10.2.1. By Therapy By Therapy By Therapy By Therapy
10.2.2. 10.2.2. By Source of Cell By Source of Cell By Source of Cell By Source of Cell
10.2.3. 10.2.3. By Scale of Operation By Scale of Operation By Scale of Operation By Scale of Operation
10.2.4. 10.2.4. By Source By Source By Source By Source
10.2.5. 10.2.5. By Application By Application By Application By Application
10.2.6. 10.2.6. By End User By End User By End User By End User
10.2.7. 10.2.7. By Country By Country By Country By Country
10.3. South America Country Analysis South America Country Analysis South America Country Analysis South America Country Analysis South America Country Analysis South America Country Analysis
10.3.1. 10.3.1. Brazil Cell Therapy Manufacturing Market Outlook Brazil Cell Therapy Manufacturing Market Outlook Brazil Cell Therapy Manufacturing Market Outlook Brazil Cell Therapy Manufacturing Market Outlook
10.3.1.1. 10.3.1.1. Market Size Forecast Market Size Forecast
10
11

• Table of Contents

S. No. Contents Contents Contents
10.3.1.1.1. By Value
10.3.1.2. Market Share Forecast Market Share Forecast
10.3.1.2.1. By Therapy
10.3.1.2.2. By Source of Cell
10.3.1.2.3. By Scale of Operation
10.3.1.2.4. By Source
10.3.1.2.5. By Application
10.3.1.2.6. By End User
10.3.2. Argentina Cell Therapy Manufacturing Market Outlook Argentina Cell Therapy Manufacturing Market Outlook Argentina Cell Therapy Manufacturing Market Outlook
10.3.2.1. Market Size Forecast Market Size Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share Forecast Market Share Forecast
10.3.2.2.1. By Therapy
10.3.2.2.2. By Source of Cell
10.3.2.2.3. By Scale of Operation
10.3.2.2.4 By Source
10.3.2.2.5. By Application
10.3.2.2.6. By End User
10.3.3. Colombia Cell Therapy Manufacturing Market Outlook Colombia Cell Therapy Manufacturing Market Outlook Colombia Cell Therapy Manufacturing Market Outlook
10.3.3.1. Market Size Forecast Market Size Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share Forecast Market Share Forecast
10.3.3.2.1. By Therapy
10.3.3.2.2. By Source of Cell
11
12

• Table of Contents

S. No. Contents Contents Contents
10.3.3.2.3. By Scale of Operation
10.3.3.2.4. By Source
10.3.3.2.5. By Application
10.3.3.2.6. By End User
11. Middle East Africa Cell Therapy Manufacturing Market Outlook Middle East Africa Cell Therapy Manufacturing Market Outlook Middle East Africa Cell Therapy Manufacturing Market Outlook Middle East Africa Cell Therapy Manufacturing Market Outlook Middle East Africa Cell Therapy Manufacturing Market Outlook
11.1. Market Size Forecast Market Size Forecast Market Size Forecast Market Size Forecast
11.1.1. By Value By Value By Value
11.2. Market Share Forecast Market Share Forecast Market Share Forecast Market Share Forecast
11.2.1. By Therapy By Therapy By Therapy
11.2.2. By Source of Cell By Source of Cell By Source of Cell
11.2.3. By Scale of Operation By Scale of Operation By Scale of Operation
11.2.4. By Source By Source By Source
11.2.5. By Application By Application By Application
11.2.6. By End User By End User By End User
11.2.7. By Country By Country By Country
11.3. Middle East Africa Country Analysis Middle East Africa Country Analysis Middle East Africa Country Analysis Middle East Africa Country Analysis
11.3.1. Israel Cell Therapy Manufacturing Market Outlook Israel Cell Therapy Manufacturing Market Outlook Israel Cell Therapy Manufacturing Market Outlook
11.3.1.1. Market Size Forecast Market Size Forecast
11.3.1.1.1. By Value
11.3.1.2. Market Share Forecast Market Share Forecast
11.3.1.2.1. By Therapy
11.3.1.2.2. By Source of Cell
11.3.1.2.3. By Scale of Operation
11.3.1.2.4. By Source
12
13

• Table of Contents

S. No. Contents Contents Contents
11.3.1.2.5. By Application
11.3.1.2.6. By End User
11.3.2. South Africa Cell Therapy Manufacturing Market Outlook South Africa Cell Therapy Manufacturing Market Outlook South Africa Cell Therapy Manufacturing Market Outlook
11.3.2.1. Market Size Forecast Market Size Forecast
11.3.2.1.1. By Value
11.3.2.2. Market Share Forecast Market Share Forecast
11.3.2.2.1. By Therapy
11.3.2.2.2. By Source of Cell
11.3.2.2.3. By Scale of Operation
11.3.2.2.4 By Source
11.3.2.2.5. By Application
11.3.2.2.6. By End User
11.3.3. Saudi Arabia Cell Therapy Manufacturing Market Outlook Saudi Arabia Cell Therapy Manufacturing Market Outlook Saudi Arabia Cell Therapy Manufacturing Market Outlook
11.3.3.1. Market Size Forecast Market Size Forecast
11.3.3.1.1. By Value
11.3.3.2. Market Share Forecast Market Share Forecast
11.3.3.2.1. By Therapy
11.3.3.2.2. By Source of Cell
11.3.3.2.3. By Scale of Operation
11.3.3.2.4. By Source
11.3.3.2.5. By Application
11.3.3.2.6. By End User
11.3.4. UAE Cell Therapy Manufacturing Market Outlook UAE Cell Therapy Manufacturing Market Outlook UAE Cell Therapy Manufacturing Market Outlook
11.3.4.1. Market Size Forecast Market Size Forecast
13
14

• Table of Contents

S. No. Contents Contents Contents
11.4.2.1.1. By Value
11.4.2.2. Market Share Forecast Market Share Forecast
11.4.2.2.1. By Therapy
11.4.2.2.2. By Source of Cell
11.4.2.2.3. By Scale of Operation
11.4.2.2.4 By Source
11.4.2.2.5. By Application
11.4.2.2.6. By End User
12. Market Dynamics Market Dynamics Market Dynamics
12.1.. Drivers Drivers Drivers Drivers
12.2. Challenges Challenges Challenges Challenges
13. Market Trends and Developments Market Trends and Developments Market Trends and Developments Market Trends and Developments Market Trends and Developments
14. Clinical Trials Clinical Trials Clinical Trials Clinical Trials Clinical Trials
15. Patent Analysis Patent Analysis Patent Analysis Patent Analysis Patent Analysis
16. Competitive Landscape Competitive Landscape Competitive Landscape
16.1. Novartis AG Novartis AG Novartis AG Novartis AG
16.2. F.Hoffmann La Roche AG F.Hoffmann La Roche AG F.Hoffmann La Roche AG F.Hoffmann La Roche AG
16.3. Gilead Sciences, Inc. Gilead Sciences, Inc. Gilead Sciences, Inc. Gilead Sciences, Inc.
16.4. Thermo Fischer Scientific, Inc. Thermo Fischer Scientific, Inc. Thermo Fischer Scientific, Inc. Thermo Fischer Scientific, Inc.
16.5. Catalent, Inc. Catalent, Inc. Catalent, Inc. Catalent, Inc.
16.6. JSR Life Sciences LLC (KBI Biopharma Inc) JSR Life Sciences LLC (KBI Biopharma Inc) JSR Life Sciences LLC (KBI Biopharma Inc) JSR Life Sciences LLC (KBI Biopharma Inc)
16.7. Waisman Center (Waisman Biomanufacturing) Waisman Center (Waisman Biomanufacturing) Waisman Center (Waisman Biomanufacturing) Waisman Center (Waisman Biomanufacturing)
16.8. Cell and Gene Therapy Catapult Cell and Gene Therapy Catapult Cell and Gene Therapy Catapult Cell and Gene Therapy Catapult
14
15

• Table of Contents

S. No. Contents
16.9. Merck KGaA Merck KGaA
16.10. Lonza Group Lonza Group
16.11. Oxford Biomedica Plc Oxford Biomedica Plc
16.12. WuXi AppTec WuXi AppTec
16.13. Charles River Laboratories International Inc. Charles River Laboratories International Inc.
16.14. Institut Merieux (ABL Inc.) Institut Merieux (ABL Inc.)
16.15. BioCentriq BioCentriq
16.16. Centre for Commercialization of Regenerative Medicine (CCRM) Centre for Commercialization of Regenerative Medicine (CCRM)
16.17. Fujifilm Holdings Corporation (Fujifilm Cellular Dynamics) Fujifilm Holdings Corporation (Fujifilm Cellular Dynamics)
16.18. Amgen Inc. Amgen Inc.
16.19. Bluebird Bio Inc. Bluebird Bio Inc.
16.20. Takeda Pharmaceutical Company Limited Takeda Pharmaceutical Company Limited
17. Strategic Recommendations Strategic Recommendations Strategic Recommendations
18. About us Disclaimer About us Disclaimer About us Disclaimer
15
16
Product Overview
17

• Scope of Report
• Product of Interest (POI) Cell Therapy
  Manufacturing

Cell therapies comprise the use of cells from
different sources to treat, manage and alter the
course of diseases that cannot be treated or
managed through existing pharmaceutical drugs and
treatments. Cell therapy manufacturing begins
with collecting cells from the patient or donor.
This cell collection takes place at a clinical
facility and then ends with administering the
final drug product to the patients. Between the
collection of cells and administration to the
patient, many steps are involved in the entire
process. All this is a part of cell therapy
manufacturing.
Market Segmentation

BY REGION
BY THERAPY
BY SCALE OF OPERATION
BY APPLICATION

• Oncology
• Cardiovascular Diseases
• Orthopedic Diseases
• Others

• Stem Cell Therapies
• T-Cell Therapies
• Dendritic Cell Therapies
• Natural Killer Cells

• Clinical
• Preclinical
• Commercial

• North America
• Europe
• Asia Pacific
• South America
• Middle East Africa

BY END USER
BY SOURCE
BY SOURCE OF CELL

• In-House
• Contract Manufacturing

• Pharmaceutical Biotechnology Companies
• Academic Research Institutes
• Others

• Autologous
• Allogenic

17
18

• Product Overview

• Cell therapy is a treatment in which living cells
  are injected into a patient to cure various
  ailments. This technique involves replacing sick
  or defective cells with healthy ones that behave
  normally.
• Due to their ability to specialize in specific
  cells required for healing damaged or
  malfunctioning tissues or cells, stem cells are
  the most commonly used cells for such therapies.
• Types of Therapies
• T- Cell Therapy T-cell therapy is a treatment in
  which a patient's T cells (a kind of immune cell)
  are genetically modified to bind to cancer cells
  and kill them.
• Stem Cell Therapy Stem cell treatment, also
  known as regenerative medicine, involves using
  stem cells or their products to stimulate the
  repair of sick, dysfunctional, or wounded tissue.
• Dendritic cells Therapy Dendritic cells are
  trained to recognize pathogenic agents, absorb
  them, and then attack them. In this approach, the
  bodys overall immune system is activated.
• Natural Killer Cell Therapy A new approach that
  uses immune cells to attack tumors, has emerged
  as one of the most promising breakthroughs in
  cancer treatment.
• Sources of Cells
• Autologous Autologous cell therapy (ACT) is a
  novel therapeutic process that uses a patients
  own cells, which are cultured and expanded
  outside the body, and then reintroduced into the
  donor.
• Allogenic Allogenic, or universal, cell
  therapies rely on a single source of cells to
  treat many patients. Cells are collected from a
  donor sample to create a master cell bank (MCB).
  The MCB is then used as the source to create cell
  populations that are processed according to the
  demands of the specific therapy.

18
19

• Product Overview

• When it comes to allogenic cells, two models are
  preferably used in manufacturing them. These
  include a centralized manufacturing model and
  near patient manufacturing model.
• Centralized Manufacturing Model In this model, a
  central site is responsible for the production of
  cell therapy products, which are then delivered
  to the clinical administration site. This model
  is quite attractive since it allows companies to
  ensure product consistency at an affordable cost.
  However, this model depends on a complex array of
  transport and logistic services, including
  cryopreservation and specialized airfreight. This
  is a comparatively viable model for several
  products in the cell and gene therapy areas and
  tissue-based products.
• Near Patient Manufacturing Model This model came
  as an alternative to the centralized
  manufacturing model, which includes cell
  production and processing at the point-of-care
  centers. This model has an advantage in removing
  the multistep transport and logistic services
  associated with a centralized manufacturing
  model.
• These are the two models which are being used for
  manufacturing allogenic cells for use in cell
  therapies. However, a more viable model can
  leverage key concepts of centralized
  manufacturing yet close enough to the bedside to
  allow live cell transportation. These can be
  regarded as manufacturing hubs.
• Additionally, several technological advancements
  can be done in the existing models to improve
  their outcomes, such as enhancing
  cryopreservation and transportation methods to
  ensure minimal loss of therapeutic cell function
  during freezing, transit, and thawing. Also,
  live-cell transportation without compromising
  quality and allowing continuous in-transit remote
  monitoring can improve the overall treatment and
  patient outcomes.

19
20

• Product Overview

Figure Centralized Cell Therapy Manufacturing
Model
Donor Characterization
Cells CQA Defined/Standards/Reference Materials
In-process Testing/Standards
Donor Eligibility
Bioprocessing
Donor Collection
Product Release Testing
Harvest and Banking
Validations and Stability
Logistics
Cell Thawing Patient Delivery
Release Re-Testing
Product
20
21

• Product Overview

Figure Near Patient Cell Therapy Manufacturing
Model
Patient Characterization
Cells CQA Defined/Standards/Reference Materials
In-process Testing/Standards
Patient Eligibility
Bioprocessing
Patient Collection
Product Release/ Testing Standards/CQA
Harvest and Banking optional for additional doses
onsite
Validations and Stability
Logistics to bedside
Cell Thawing Patient Delivery
Release Testing
Product
21
22
Research Methodology
23

• Research Methodology

Market Profiling
Data Analysis
Data Collection
Data Validation
Developing list of respondents
Formulating Questionnaire
In-depth secondary research was conducted to
determine the overall market size, segmental
market size and top players in the global cell
therapy manufacturing market.
The data was scrutinized using MS-Excel,
statistical tools and internal proprietary
database to obtain qualitative and quantitative
insights about the global cell therapy
manufacturing market.
Data obtained as a result of primary and
secondary research was validated through rigorous
triangulation.
TechSci conducted interviews with industry
experts and industry players for data collection
and verification.
In order to conduct industry experts interviews,
TechSci formulated a detailed discussion guide.
List of industry players and industry specialists
was developed.
Primary Research
Desk Research
Company Analysis

• Recent Developments
• Market Changing Aspects/Dynamics
• Government Policies
• Final Conclusion

• Market Participants
• Key Strengths

• Identifying Key Opinion Leaders
• Questionnaire Design
• In-depth Interviews

23
24

• Research Methodology

• Baseline Methodology
• Our dedicated team of industry experts has
  monitored and analyzed various aspects of the
  global cell therapy manufacturing market. The
  team has analyzed the outlook of various segments
  of this market, while considering the major
  influencing factors such as growing prevalence of
  diseases such as cancer, cardiovascular diseases,
  among others. The study includes market
  forecasting, which would enable our clients to
  take better decisions while planning their
  strategy to achieve sustainability in the global
  cell therapy manufacturing market.
• Methodology Followed for Calculation of Market
  Size
• Market Size by Value Market size, in terms of
  value, for the year 2020 was calculated based on
  information collected through exhaustive
  secondary research and primary surveys, with
  various key opinion leaders/stakeholders, such as
  cell therapy manufacturing companies, channel
  partners, end users, industry experts, and other
  industry participants.
• The team interviewed more than 15 cell therapy
  manufacturing companies, 300 end users and 10
  industry experts and other value chain
  stakeholders in the global cell therapy
  manufacturing market to obtain the overall market
  size between 2016 and 2020, which was validated
  by the Delphi technique. Taking standard
  deviation into consideration, the market size was
  averaged out, to arrive at the market size data.
• Respondents were asked about the current and
  future market growth rates, market shares by
  therapy, by source of cell, by scale of
  operation, by source, by application, by end
  user, by region and by company. Removing the
  outlier responses, the geometric mean of growth
  estimates and category wise revenue shares
  generated across various segments were
  considered, to arrive at the

24
25

• Research Methodology

• final revenue shares. Revenue shares generated
  across various segments were further triangulated
  based on the response received from other
  stakeholders.
• Methodology Followed for Calculation of Market
  Shares
• Market shares by therapy, by source of cell, by
  scale of operation, by source, by application, by
  end user, by region and by company were
  calculated based on the responses received
  through primary surveys with industry experts, in
  which the respondents were asked about the market
  shares or revenue generated from various segments
  of the global cell therapy manufacturing market.
  The final shares were calculated by taking the
  geometric mean of the responses gathered from key
  opinion leaders after eliminating the outliers.
• Methodology Followed for Forecasting
• TechSci Research performed periodical checks on
  data collected through the surveys with logic
  checks and analyzed the survey results in
  SPSS/Tableau Software.
• Data triangulation techniques were applied to
  fill the gaps and to present a more meaningful
  picture of the market. To forecast the global
  cell therapy manufacturing market, TechSci
  Research used various forecast techniques such
  as
• Moving Average
• Time Series Analysis
• Regression Analysis
• Econometric and Judgmental Analysis

25
26

• Research Methodology

TechSci Research used its own forecast tool,
which is based on the growth of various allied
industries in respective regions. TechSci
Research also used the impact analysis during
short, medium and long term period to estimate
the demand and to reach accurate market numbers.
The currency used in the report is the United
States Dollar (with the market size indicated in
USD million).
Partial List of Companies Interviewed Key Secondary Sources
Novartis AG F.Hoffmann La Roche AG Gilead Sciences, Inc. Thermo Fischer Scientific, Inc Catalent, Inc. JSR Life Sciences LLC (KBI Biopharma Inc) Waisman Center (Waisman Biomanufacturing) Cell and Gene Therapy Catapult Merck KGaA Lonza Group Oxford Biomedica Plc WuXi AppTec Charles River Laboratories International Inc. Institut Merieux (ABL Inc.) BioCentriq Centre for Commercialization of Regenerative Medicine (CCRM Fujifilm Holdings Corporation (Fujifilm Cellular Dynamics) Amgen Inc. Bluebird Bio Inc. Takeda Pharmaceutical Company Limited World Bank TechSci Research Proprietary Database Knowledge Repository Company Annual Reports Industry Magazines Industry Reports Food and Drug Administration (FDA) Credible Paid Databases International Diabetes Foundation Centers for Disease Control and Prevention World Health Organization National Academy of Medicine
26
27

• Industry Brief

Consistent research and studies are driving the
growth in Global Cell therapy manufacturing
Market in the forecast period, 2022-2026. Accordin
g to TechSci Research report, Cell Therapy
Manufacturing Market - Global Industry Size,
Share, Trends, Competition, Opportunity and
Forecast, 2016-2026, the global Cell Therapy
Manufacturing market stood at USD3123.44 million
in 2020 and is expected to grow at a steady CAGR
of 12.00 during the forecast period on account
of consistent research and studies related to
cell therapies. Cell therapy is a
biotechnological procedure where viable cells are
injected, grafted, or implanted into the human
body that requires it as a part of a medical
treatment. Major example can be understood using
T-cells for the treatment of cancerous cells in
the patient. The growing prevalence of various
chronic diseases such as cancer, diabetes, and
cardiovascular diseases has significantly
increased the patient pool worldwide suffering
from these diseases. This in turn has
significantly increased the demand for cell
therapy manufacturing to find new treatments for
the severe diseases. The expansion of the
biopharmaceutical companies and biotechnological
institutes is also supporting the growth of the
global cell therapy manufacturing market in the
upcoming five years. Due to the sudden outbreak
of COVID-19 pandemic, there has been a rapid
increase in research and development of
cell-based vaccines for the treatment of
COVID-19. The presence of government and
commercial funding agencies that are continually
issuing grants to support projects at various
phases of clinical trials can be ascribed to the
growing number of ongoing clinical studies. Apart
of that, high cost of cellular therapies, dearth
of skilled healthcare professionals, large scale
manufacturing, stringent regulatory policies, and
lack of awareness are some of the major factors
that are inhibiting the growth of Cell Therapy
Manufacturing Market. The global Cell Therapy
Manufacturing market is segmented based on
therapy, source of cell, scale of operation,
source, application, end user, company, and
regional distribution. Based on therapy, the
market is segmented into T-Cell Therapies,
Dendritic Cell Therapies, Tumor Cell Therapies,
Stem Cell Therapies. Stem cell therapies is
anticipated to hold the largest share of the
market and dominate the segment in the next five
years on account of rising research and
development in the area. Stem cells therapy is
utilized for the cure of various chronic diseases
and the consistent efforts to provide the best
available treatment to the patients. Based
on Source of Cell, the market is divided into
Autologous and Allogenic. In terms of Scale of
Operation, the market can be categorized into
Preclinical, Clinical and Commercial. By Source,
the market is fragmented into In-House
Manufacturing and Contract Manufacturing. Based
on application, the market can be fragmented
into Oncology, Cardiovascular Diseases,
Orthopedic Diseases and Others. Oncology is
expected to generate the maximum revenue shares
in the market and assert its dominance over the
market on the account of increasing research and
studies in the field of oncology. Moreover, the
number of cases where the patient is suffering
due to cancer or different type of cancers is
also multiplying globally. Cell therapy is one of
the most incorporated procedures for
understanding the growth of cancerous cells and
to overcome the cancer-causing cells in the body.
The method is actively utilized and is thus
aiding in the growth of the application. Based on
end user, the market can be segmented
into Pharmaceutical Biotechnology Companies,
Academic Research Institutes and Others. Key
market players in the global cell therapy
Manufacturing market include Novartis AG, F.
Hoffmann-La Roche AG, Gilead Sciences, Inc.,
Thermo Fischer Scientific, Inc., Catalent, Inc.,
JSR Life Sciences LLC (KBI Biopharma Inc),
Waisman Center (Waisman Biomanufacturing), Cell
and Gene Therapy Catapult, Merck KGaA, Lonza
Group, Oxford Biomedica Plc, WuXi AppTec, Charles
River Laboratories International Inc., Institut
Merieux (ABL Inc.), BioCentriq, Centre for
Commercialization of Regenerative Medicine
(CCRM), Fujifilm Holdings Corporation (Fujifilm
Cellular Dynamics), Amgen Inc., Bluebird Bio
Inc., Takeda Pharmaceutical Company
Limited Global Cell Therapy Manufacturing market
is consolidated with a lot of well-established
players having presence in several countries
with several domestic players possessing
leadership in certain regions and countries,
among others. Novartis AG holds the highest
market share and is among the top five market
players globally. F. Hoffmann La Roche AG ranks
second in terms of market share in the overall
cell therapy manufacturing market. The company
has a strong presence worldwide and a huge brand
value. People in emerging countries are also
aware of the presence, product portfolio and
business of the company and are preferring it
over other competitor brands. Additionally, there
are other prominent players such as Gilead
Sciences, Inc., Thermo Fischer Scientific, Inc.,
Catalent, Inc., JSR Life Sciences LLC (KBI
Biopharma Inc), Waisman Center (Waisman
Biomanufacturing), Cell and Gene Therapy
Catapult, Merck KGaA, Lonza Group and others,
which are holding a significant position in the
global Cell Therapy Manufacturing market. The
Asia Pacific region will register the fastest
CAGR during the forecast period. This can be
attributed to the large and growing prevalence of
chronic diseases such as Cancer, Cardiovascular
Diseases, Diabetes, and others in the region
especially in countries like China, India, and
Japan. Additionally, supportive government
policies and healthcare schemes launched by them
across different countries in the region is
expected to support market growth. For instance,
in 2019, the Australian government announced an
USD57 million investment into the manufacturing
of CAR-T at the Peter MacCallum Cancer Center,
ensuring that all stages of the CAR-T pathway are
able to remain in Australia. said Mr. Karan
Chechi, Research Director with TechSci Research,
a research based Global management consulting
firm.
27
28

• Sample Data - Snapshot

Global Cell Therapy Manufacturing Market Size, By
Value (USD Million), 2016-2026F
CAGR 2016-2020 By Value xx
CAGR 2021E-2026F By Value xx
Europe Cell Therapy Manufacturing Market Share,
By Therapy, By Value, 2016-2026F
United Kingdom Cell Therapy Manufacturing Market
Share, By Scale of Operation, By Value, 2016-2026F
United Kingdom Cell Therapy Manufacturing Market
Share, By Source of Cell, By Value, 2016-2026F
28
29

• Report Ordering

• Report Name Global Cell Therapy
  Manufacturing Market
• FORECAST AND OPPORTUNITIES
• 2016 2026

License Type Price
Single User License 4900
Multi-User License 5900
Custom Research License 8900
To View Sample OR Purchase Report  
29
30
About Us Disclaimer
TechSci Research is a global market research and
consulting company with offices in the US, UK and
India. TechSci Research provides market research
reports in number of areas to organizations. The
company uses innovative business models that
focus on improving productivity, while ensuring
creation of high-quality reports. The proprietary
forecasting models use various analyses of both
industry-specific and macroeconomic variables on
a state-by-state basis to produce a unique
bottom-up model of a country, regional and
global industry prospects. Combined with the
detailed analysis of company activity and
industry trends, the result is a uniquely rich
evaluation of the opportunities available in the
market.
Related Reports

• Global CAR-T Cell Therapy Market, By Product Type
  (Yescarta, Kymriah (Tisagenlecleucel), Tecartus
  (brexucabtagene autoleucel), Breyanzi
  (lisocabtagene maraleucel), Abecma (idecabtagene
  vicleucel), Others), By Tumor Type (Hematological
  Malignancies, Solid Tumors), By Indication
  (DLBCL, ALL, FL, MCL, Others), By Treatment Type
  (Single Treatment, Combination Treatment), By
  Targeted Antigen (CD 19, BCMA (B-Cell Maturation
  Antigen), Others), By End User (Hospitals,
  Speciality Clinics, Ambulatory Surgical Centers,
  Others), By Region, Competition Forecast
  Opportunities, 2026
• Global Regenerative Medicine Market, By Therapy
  (Cell-Based Immunotherapy Cell Therapy, Gene
  Therapy, Others), By Application (Musculoskeletal
  Disorders, Wound Care, Others), By Material
  (Synthetic Material, Biologically Derived
  Material, Others), By Cell (Autologous,
  Allogenic), By Product (Biologic, Cell -based
  Medical Devices, Others), By Technique
  (Microfracture, Mosaicplasty), By Distribution
  Channel (Hospitals, Clinics , Others), By Region
  Opportunities, 2025

TechSci Research North America 708 Third
Avenue, Manhattan, New York, United States Tel
1- 646- 360- 1656 Email sales_at_techsciresearch.co
m www.techsciresearch.com
TechSci Research Europe 54, Old brook,
Bretton, Peterborough, United Kingdom Email
sales_at_techsciresearch.com www.techsciresearch.com
TechSci Research Asia Pacific B 44, Sector
57, Noida, National Capital Region, U.P. -
India Tel [phone] Email
sales_at_techsciresearch.com www.techsciresearch.com
Disclaimer
The contents of this report are based on
information generally available to the public
from sources believed to be reliable. No
representation is made that it is timely,
accurate or complete. TechSci Research has taken
due care and caution in compilation of data as
this has been obtained from various sources
including which it considers reliable and first
hand. However, TechSci Research does not
guarantee the accuracy, adequacy or completeness
of any information and it is not responsible for
any errors or omissions or for the results
obtained from the use of such information and
especially states that it has no financial
liability whatsoever to the subscribers / users
of this report. The information herein, together
with all estimates and forecasts, can change
without notice. All the figures provided in this
document are indicative of relative market size
and are strictly for clients internal
consumption. Usage of the same for purpose other
than internal will require prior approval of
TechSci Research.